**Epstein-Barr Virus-Positivity in Tumor has no Correlation with the Clinical Outcomes of Patients with Angioimmunoblastic T-cell Lymphoma**

Yuna Lee, M.D.\(^1\), Keun-Wook Lee, M.D.\(^2\), Jee-Hyun Kim, M.D.\(^2\), Soo-Mee Bang, M.D.\(^2\), Jong Seok Lee, M.D.\(^2\), Byeong-Bae Park, M.D.\(^3\), Won Seok Kim, M.D.\(^3\), Cheolwon Suh, M.D.\(^4\), Jung Hun Kang, M.D.\(^5\), Baek Yeol Ryoo, M.D.\(^6\), Jae Hoon Lee, M.D.\(^1\) and Dong Bok Shin, M.D.\(^1\)

Division of Hematology Oncology, Department of Internal Medicine, Gachon University Gil Medical Center, Inchon, Korea\(^1\); Division of Hematology-Oncology, Department of Internal Medicine, Seoul National University Bundang Hospital, Seongnam, Korea\(^2\); Division of Hematology-Oncology, Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea\(^3\); Division of Hematology-Oncology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea\(^4\); Department of Hematology-Oncology, Gyeongsang National University Hospital, Jinju, Korea\(^5\); Department of Hematology-Oncology, Korea Cancer Center Hospital, Seoul, Korea\(^6\)

**Background/Aims:** Epstein-Barr virus (EBV) is involved in the pathogenesis of angioimmunoblastic T-cell lymphoma (AILT), but its precise role and prognostic impact are not clear. This study aimed to evaluate the incidence of EBV-positivity in the tumor and bone marrow (BM) samples from AILT patients, and their correlations with the clinical variables and patient survival.

**Methods:** Seventy AILT cases were identified over a period of 8 years. Twenty-seven cases were investigated for their EBV tumor status, and 10 BM samples of these patients were investigated for their EBV status with using in situ hybridization (ISH). EBV PCR was performed for the BM mononuclear cells in 8 cases.

**Results:** Among the 27 tumor specimens, ten (37%) were EBV-positive. Only CD20-negativity in tumor correlated with the EBV-positivity (p=0.035). In 13 (48%) patients, gross tumor involvement was recognized by hematoxylin-eosin staining at the time of diagnosis. Among the 10 patients who had additional BM slides available, there were 3 with BM involvement, and none showed EBV positive results on ISH. EBV PCR of the BM mononuclear cells revealed one-positive case among 8 patients. This patient was negative for both BM involvement and EBV ISH. The median overall survival of the 25 treated patients was 48.9 months (95% CI: 18.6^-79.2 months). Neither overall survival nor progression-free survival was related with EBV-positivity of the tumor.

**Conclusions:** EBV-positivity of tumor had no impact on the prognosis of AILT patients.

**Key Words:** Epstein-Barr virus; Angioimmunoblastic T-cell lymphoma; Survival

---

**INTRODUCTION**

More than 90% of adults worldwide are infected with Epstein-Barr virus (EBV) and they carry the virus as a life-long persistent infection, with latent infection of their B lymphocytes and viral production into their saliva\(^1\)\(^2\). EBV is associated with
the pathogenesis of several different types of aggressive non-Hodgkin’s lymphoma (NHL) and Hodgkin’s lymphoma. In 1976, screening 27 cases of lymphoid tissue lesions for EBV-DNA with using nucleic acid reassociation kinetics led to the detection of one virus-positive case of angioimmunoblastic T-cell lymphoma (AILT)9. Many subsequent studies have demonstrated the presence of EBV in 58–97% of all AILT cases in either the T or B cells4-7). The clinical presentation of AILT is usually systemic disease with B symptoms, while the pathology reveals a polymorphous infiltrate involving the lymph nodes with a prominent proliferation of endothelial and dendritic cells8). Some patients go on to develop a secondary EBV-positive large B-cell lymphoma.

A recent study demonstrated that the presence of EBV-DNA obtained by performing real-time quantitative PCR and Southern blotting analysis of tumor tissue had no significant effect on the clinical outcome of AILT patients9). As for the patients with nasal NK/T-cell lymphoma, a EBV-positive tumor is a prerequisite for making the diagnosis10). A recent study proved that minimal EBV involvement in the bone marrow (BM) was a powerful prognostic marker11).

Therefore, we performed this study to evaluate the rate of EBV-positivity in tumor and BM and their prognostic values for the clinical outcome of AILT patients.

**MATERIALS AND METHODS**

**Patients**

Over a period of 8 years (from August 1998 to July 2005), 70 AILT cases from 8 medical centers were identified based on the histological and immunohistochemical criteria with using the REAL and/or WHO classifications. We enrolled 27 patients who had additional tissue slides for EBV in situ hybridization (ISH). Ten patients’ BM slides were also analyzed in this study. Eight patients had their cryopreserved BM mononuclear cells for performing EBV DNA PCR.

All the patients were staged according to the Ann Arbor staging system. The complete staging procedures included physical examination, chest X-ray, complete blood cell counts, blood biochemistry, computed tomography of the thorax, abdomen and pelvis, and BM aspiration and biopsy. The clinical and laboratory records were reviewed for all the patients.

**Treatment**

The chemotherapy regimens included CHOP (cyclophosphamide, Hydroxydaunomycin, vincristin and prednisone), CHOP-E (etoposide) or ESHAP (etoposide, solumedrol, cytarabine and cisplatin).

ISH for EBV in the tumor and BM biopsy12

We performed EBV ISH on 27 tumor specimens and 10 BM biopsy specimens. The paraffin-embedded sections of the biopsy specimens were deparaffinized with xylene, and this was followed by treatment with proteinase K. The sections were then hybridized with fluorescein isothiocyanate-conjugated EBV oligonucleotides (Novocastra, Newcastle, U.K.) that were complementary to the nuclear RNA protein of the EBER1 and EBER2 genes. Positive labeling was identified only when the cells showed nuclear staining with EBV oligonucleotide. As negative controls, we used EBV negative lymphoid tissues and a hybridization mixture without the EBV oligonucleotides. As the internal positive control, the tumor and BM slides of patient with NK-cell leukemia were used.

**Sample DNA preparation and EBV PCR11**

The BM mononuclear cells from 8 patients were studied by performing EBV PCR. EBV DNA was extracted from the patients’ BM aspiration samples (frozen monocytes) with using the QIAmp DNA Blood Mini Kit (Qiagen, USA). Approximately 100ng of DNA was used for PCR reaction. The PCR primer sequences were 5’-GACGAGGGGCCAGGTACAGG-3’ and 3’-GCAGCCAATGCAACTTGGACGTTTTAGG-5’, respectively. The PCR reaction was performed using the primer set (Maxim biotech, Inc, USA). The PCR mixture contained 250 μL of the pre-mixed primers and 750 μL of optimized PCR buffer. The PCR was performed in a total volume of 50 μL, which contained 10,0 L of DNA, 39,8 L of the PCR mixture and 0,2 μ L of Taq DNA polymerase. The amplification reaction was performed for 37 cycles under the following conditions: initially, 96°C for 1min for activation (one cycle), followed by a denaturation phase at 94°C for 1min, an annealing phase at 58°C for 1min and an extension phase at 72°C for 1min (35 cycles). Another 10 min extension phase at 72°C was performed at the end of each round of PCR. Ten microliters of the PCR products were subjected to electrophoresis (100V, 25min) on a 2% agarose gel, and the products were stained with ethidium bromide. The presence or absence of specific PCR targets was observed under UV illumination.

**Statistical analysis**

Overall survival was measured from the time of diagnosis to death or to the last follow-up. The survival curves were calculated using the Kaplan-Meier method and they were then compared using the log-rank test. Other clinical factors were compared using chi-square tests or t-tests. Differences were considered statistically significant if the p value was <0.05. All statistical analyses were performed using the SPSS for Windows 13.0 statistical package (SPSS Inc., Chicago, IL).
Table 1. Clinicopathologic findings of the 27 patients with angioimmunoblastic T-cell lymphoma

| Case No | Age(yr)/Gender | Initial stage | CD 20 in tumor | EBV ISH in tumor | BM invasion at diagnosis | IPI | Survival (months) |
|---------|----------------|---------------|----------------|-----------------|-------------------------|-----|------------------|
| 1       | 54/M           | 4A            | -              | -               | +                       | 2   | A (6.6)         |
| 2       | 49/M           | 3A            | +              | -               | -                       | 1   | A (1.2)         |
| 3       | 66/M           | 4A            | -              | +               | +                       | 3   | A (20.7)        |
| 4       | 50/M           | 4A            | -              | +               | +                       | 4   | A (13.3)        |
| 5       | 52/F           | 3B            | -              | -               | -                       | 2   | A (2.5)         |
| 6       | 57/M           | 4B            | -              | +               | -                       | 3   | D (1.7)         |
| 7       | 54/M           | 3A            | -              | +               | -                       | 1   | D (12.4)        |
| 8       | 62/F           | 4B            | -              | +               | -                       | 4   | A (11.9)        |
| 9       | 38/M           | 4B            | -              | -               | -                       | 2   | D (11.7)        |
| 10      | 17/F           | 4B            | -              | -               | +                       | 3   | A (75.6)        |
| 11      | 57/F           | 3B            | NE             | -               | -                       | 4   | D (50.7)        |
| 12      | 31/F           | 4B            | -              | +               | +                       | 3   | A (21.5)        |
| 13      | 68/M           | 4B            | -              | +               | +                       | 5   | D (0.5)         |
| 14      | 51/M           | 3B            | -              | -               | -                       | 2   | D (48.9)        |
| 15      | 53/M           | 3B            | -              | +               | -                       | 3   | A (35.5)        |
| 16      | 64/M           | 4B            | +              | -               | +                       | 3   | D (23.7)        |
| 17      | 42/F           | 4B            | -              | -               | -                       | 4   | D (5.3)         |
| 18      | 75/M           | 3B            | NE             | -               | -                       | 4   | D (2.3)         |
| 19      | 27/F           | 4B            | +              | -               | +                       | 4   | A (37.8)        |
| 20      | 58/M           | 4B            | +              | -               | +                       | 3   | A (36.3)        |
| 21      | 67/M           | 4A            | -              | +               | +                       | 2   | A (13.3)        |
| 22      | 71/M           | 4A            | -              | +               | +                       | 4   | D (3.1)         |
| 23      | 66/M           | 4B            | -              | +               | +                       | 3   | A (36.8)        |
| 24      | 64/F           | 4AE           | -              | +               | +                       | 4   | A (0.3)         |
| 25      | 71/M           | 3B            | +              | -               | -                       | 4   | D (21.4)        |
| 26      | 63/F           | 4BE           | +              | -               | -                       | 4   | D (2.8)         |
| 27      | 74/M           | none          | -              | -               | NE                      | NE  | D (0.5)         |

NE, not evaluated; A, alive; D, death.

RESULTS

Clinical features

One patient among the 27 AILT patients refused any further staging work-up. The clinicopathologic data of the 27 patients are summarized in Table 1. This series included 19 men and 8 women with ages from 17 to 75 (median age: 57 years-old). All the patients except one had stage III or IV disease. Anemia was detected at diagnosis in 10 patients: two of them had autoimmune hemolytic anemia. Twenty five patients received chemotherapy, including 23 patients who received CHOP, 1 patient who received CHOP-E and 1 patient who received ESHAP, while 2 patients received only supportive care.

EBV ISH in the tumor and its clinical impact

Among the tumor specimens obtained at the time of the initial diagnosis from the 27 AILT patients, 10 were positive for EBV ISH, The correlations of the clinical status, such as the international prognostic index (IPI) score, age, stage and other laboratory findings, with the EBV status of tumor are summarized in Table 2. Only CD20 negativity in the tumor was significant correlated with EBV-positivity in the tumor (p=0.035).

The median overall survival and progression-free survival of the 25 treated patients were 48.9 months (95% CI: 18.6~79.2 months) and 32.3 months (95% CI: 11.5~53.1 months) (Figure 1A). There were no significant correlations between EBV-positivity in tumor and the overall or progression-free survival.

BM involvement by Hematoxylin-eosin staining, ISH or PCR

In 13 of the 26 AILT patients, gross tumor involvement was recognized in the initial BM sample by hematoxylin-eosin staining (H-E stain). None of the 10 patients who had additional BM slides available revealed EBV-positivity on BM ISH. Among these 10 patients, 3 patients showed BM involvement by H-E staining, but this was not identified on EBV ISH (Figure 2) or PCR. Yet one patient among the 5 patients without BM involvement showed a positive band on PCR (Figure 3). BM involvement by H-E staining was not related with the clinical status as defined by the IPI, age, stage and laboratory findings (Table 3). The overall survival and progression-free survival for the treated patients among the 13 patients with BM involvement, according to H-E staining, were longer than those for the patients without
Table 2. Correlation between tumor EBV positivity on ISH and the clinico-laboratory findings

| Variables | Category | EBV ISH-positive | EBV ISH-negative | p value |
|-----------|----------|-----------------|-----------------|---------|
| Age       | \( \leq 60 \text{ yrs} \) | 4               | 11              | 0.212   |
|           | \( > 60 \text{ yrs} \) | 6               | 6               | 0.112   |
|           | mean     | 61.4            | 52.2            |         |
| H&N LN    | not involved | 0              | 4               | 0.097   |
|           | involved  | 10              | 13              |         |
| CD20      | Positive  | 0               | 6               | 0.035   |
|           | Negative  | 10              | 9               |         |
| Hemoglobin| \( \geq 10 \) | 7               | 9               | 0.384   |
|           | \( < 10 \) | 3               | 8               |         |
|           | mean     | 11.0            | 10.3            |         |
| WBC       | \( \leq 10K \) | 8               | 12              | 0.590   |
|           | \( > 10K \) | 2               | 5               |         |
| LDH       | \( \leq \text{UNL} \) | 5               | 3               | 0.093   |
|           | \( > \text{UNL} \) | 5               | 13              |         |
|           | mean     | 495             | 662             |         |
| stage     | I-II     | 0               | 1               | 0.434   |
|           | III-IV   | 10              | 16              |         |
| PS        | 0-1      | 5               | 8               | 0.883   |
|           | 2-4      | 5               | 9               |         |
| B symptom | no       | 5               | 3               | 0.075   |
|           | Yes      | 5               | 14              |         |

BM involvement \((p=0.054\text{ and } p=0.005\text{, respectively; Figure 1B, 1C})\).

Clinical factors affecting survivals

On univariate analysis, older age, male gender, pulmonary parenchymal involvement, the presence of edema and negative BM were adverse factors for progression-free survival and overall survival. Male gender \((p=0.041\text{, } p=0.044\text{, respectively})\), pulmonary parenchymal involvement \((p=0.039\text{, } p=0.042\text{, respectively})\) and negative BM \((p=0.004\text{, } p=0.005\text{, respectively})\) all significantly shortened the progression-free survival on multivariate analysis. Among the significant factors for overall survival, male gender \((p=0.078\text{, } p=0.044\text{, respectively})\) and
Table 3. Correlation between BM involvement and the clinicolaboratory findings

| Variables | Category | BM involvement | No BM involvement | ρ value |
|-----------|----------|----------------|-------------------|---------|
| Age       | ≤ 60 yrs | 6              | 9                 | 0.234   |
|           | > 60 yrs | 7              | 4                 |         |
|           | mean     | 54.1           | 55.7              | 0.780   |
| H&N LN    | not involved | 1              | 3                 | 0.277   |
|           | involved  | 12             | 10                |         |
| CD20      | Positive | 3              | 3                 | 0.329   |
|           | Negative | 10             | 8                 |         |
| Hemoglobin| ≥10      | 6              | 10                | 0.107   |
|           | <10      | 7              | 3                 |         |
|           | mean     | 9.96           | 11.45             |         |
| WBC       | ≤10K     | 9              | 11                | 0.352   |
|           | >10K     | 4              | 2                 |         |
| LDH       | ≤ UNL    | 4              | 4                 | 1.000   |
|           | > UNL    | 9              | 9                 |         |
|           | mean     | 631.2          | 565.5             |         |
| PS        | 0~1      | 7              | 6                 | 0.695   |
|           | 2~4      | 6              | 7                 |         |
| B symptom | no       | 6              | 2                 | 0.089   |
|           | Yes      | 7              | 11                |         |

Figure 2. In situ hybridization for EBV in the bone marrow biopsies. Positive staining for EBV in a case with NK/T-cell leukemia (A), and negative staining in a patient with angioimmunoblastic T-cell lymphoma (B)

negative BM (ρ=0.080) also had modest significance on multivariate analysis.

DISCUSSION

EBV DNA was detected in Burkitt’s lymphoma tissue in 1964, from non-Hodgkin’s lymphoma in the early 1980s and from T-cell lymphoma and Hodgkin’s lymphoma in the late 1980s. Clonotypic proliferation of EBV has been demonstrated in the neoplastic cells of lymphoid malignancies, which suggests a causative role for EBV in their tumorigenesis. The cells infected with EBV are thought to avoid apoptosis by expressing EBV latent membrane proteins (LMP) (CD 40 homologue) and 2a (BCR engagement). Infected B cells are delivered by binding to helper T cells via the CD40 molecule that presents on the B cell surface, and by binding to the B cell receptor. The outcome of AILT is poor, with most series reporting a 5-year OS of approximately 30% and a median survival of 3 years. Several studies have been done to assess how the pathogenesis of EBV contributes to the prognosis. Anagonostopoulos et al showed the predominant infection of B cells in the nodular EBV-positive cases and the predominant infection of T cells in the diffusely EBV-positive cases, and this was confirmed by double labeling for EBER and the lineage markers for all the AILT cases. Further, EBV infection of the two cell lineages would appear to be unique
to AILT as this has not yet been reported for other malignancies, but the pathway of B- and T-cell infection by EBV in AILT patients is unclear. Our study showed that CD20 negativity of a tumor was significant correlated with EBV ISH positivity \( (p=0.035) \). The expression of the CD20 antigen may be downregulated in latently EBV-infected small lymphoid cells in vivo\(^{16}\).

Our findings supported this observation. Several other articles showed the contradictory result that AILT often have increased numbers of CD20-positive cells that are also EBV-positive\(^{17-19}\). This discrepancy needs further verification. The relative lower incidence (37%) of EBV-positivity of tumor in this study was lower when compared to that (58~97%) of western studies. We used an adequate positive control, that is, EBV-positive NK/T-cell leukemia. Therefore, using more sensitive methods such as PCR to detect low copy numbers of EBV would be the next step\(^9, 20\).

Another aim of this study was to adopt the prognostic model of minimal BM involvement by EBV-positive tumor cells in NK/T-cell lymphoma and apply it to AILT. Unexpectedly, it was difficult to use EBV ISH or PCR for detecting EBV-positive tumor cells in BM, such as those EBV-positive tumor cells in NK/T-cell lymphoma. The EBV ISH or PCR results were all negative for the AILT patients with gross tumor involvement, as determined by H-E staining. This made it impossible to introduce the concept of minimal BM involvement by EBV-positive tumor cells in AILT.

Also, the results of performing EBV ISH and/or PCR for tumor or BM had no impact on the outcomes of the AILT patients in our study; this was similar to a recent Japanese study\(^9\).

Our study showed a particular result that the overall survival and progression free survival of the AILT patients with BM involvement were significant longer than those of the patients without BM involvement. Of course, the limited number of patients makes it difficult to generalize this finding. However, most AILT patients in this study were at an advanced stage of disease at the time of diagnosis. Except for stage, patient survival was significantly related to age, B cell symptoms, rash/pruritus, edema, ascites, lactate dehydrogenase, hemoglobin and the number of clinical symptoms with excluding the B symptoms of the AILT patients\(^{21}\). The presence of bulky disease (>7.5 cm), an advanced stage and bone marrow involvement did not influence survival of the patients with T-cell lymphoma in the previous studies\(^{22, 23}\). Unlike B-cell lymphoid malignancies such as diffuse large B-cell lymphoma and chronic lymphoid leukemia, BM involvement may not be a poor prognostic factor for T-cell lymphoma. A future study that would include a sufficient number of AILT patients will clarify this particular finding.

REFERENCES

1) Macsween KF, Crawford DH, Epstein-Barr virus: recent advances, Lancet Infect Dis 3:131-140, 2003
2) Thorley-Lawson DA, Gross A, Persistence of the Epstein-Barr virus and the origins of associated lymphomas, N Engl J Med 350: 1328-1337, 2004
3) Bornkamm GW, Stein H, Lennert K, Ruggeberg F, Bartels H, zur Hausen H, Attempts to demonstrate virus-specific sequences in human tumor: IV-EB viral DNA in European Burkitt’s lymphoma and immunoblastic lymphadenopathy with excessive plasmacytosis, Int J Cancer 17:177-181, 1976
4) Khan G, Norton AJ, Slavin G, Epstein-Barr virus in angioimmunoblastic T-cell lymphomas, Histopathology 22:145-149, 1993
5) Smith JL, Hodges E, Quin CT, McCarthy KP, Wright DH, Frequent T and B cell oligoclonies in histologically and immunophenotypically characterized angioimmunoblastic lymphadenopathy, Am J Pathol 156:661-669, 2000
6) Weiss LM, Jaffe ES, Liu XF, Chen YY, Shibata D, Medeiros LJ, Detection and localization of Epstein-Barr viral genomes in angioimmunoblastic T-cell lymphomas, Histopathology 22:145-149, 1993
7) Anagnostopoulos I, Hummel M, Finn T, Tiemann M, Korbjrh P, Dimmeler C, Gatter K, Dallenbach F, Parwaresch MR, Stein H, Heterogeneous Epstein-Barr virus infection patterns in peripheral T-cell lymphoma of angioimmunoblastic lymphadenopathy type, Blood 80:1804-1812, 1992
8) Heslop HE, Biology and treatment of Epstein-Barr virus-associated non-hodgkin lymphomas, Hematology Am Soc Hematol Educ Program 260-268, 2005
9) Kawano R, Ohshima K, Wakamatsu S, Suzukiya J, Kikuchi M, Tamura K, Epstein-Barr virus genome level, T-cell clonality and the prognosis of angioimmunoblastic T-cell lymphoma, Haematologica 90:1192-1196, 2005
10) Hasserjian RP, Harris NL, NK-cell lymphomas and leukemias: a spectrum of tumors with variable manifestations and immunophenotype
notype, Am J Clin Pathol 127:880-886, 2007
11) Huang WT, Chang KC, Huang GC, Hsiao JR, Chen HH, Chuang SS, Chen TY, Su WC, Tsao CJ. Bone marrow that is positive for Epstein-Barr virus encoded RNA-1 by in situ hybridization is related with a poor prognosis in patients with extranodal natural killer/T-cell lymphoma, nasal type. Haematologica 90:1063-1069, 2005
12) Sung CO, Ko YH. Bone marrow is involved in less than 10% of patients with nasal-type NK/T cell lymphoma at initial diagnosis, J Korean Med Sci 19:229-233, 2004
13) Cohen JI. Epstein-Barr virus infection, N Engl J Med 343:481-492, 2000
14) Su IJ, Hsieh HC, Lin KH, Uen WC, Kao CL, Chen CJ, Cheng AL, Kadin ME, Chen JY. Aggressive peripheral T-cell lymphomas containing Epstein-Barr viral DNA: a clinicopathologic and molecular analysis, Blood 77:799-808, 1991
15) Savage KJ, Chhanabhai M, Gascoyne RD, Connors JM. Characterization of peripheral T-cell lymphomas in a single North American institution by the WHO classification, Ann Oncol 15:1467-1475, 2004
16) Herbst H, Steinbrecher E, Niedobitek G, Young LS, Brooks L, Muller-Lantzsch N, Stein H. Distribution and phenotype of Epstein-Barr virus-harboring cells in Hodgkin’s disease, Blood 80:484-491, 1992
17) Higgins JP, van de Rijn M, Jones CD, Zehnder JL, Warnke RA. Peripheral T-cell lymphoma complicated by a proliferation of large B cells, Am J Clin Pathol 114:236-247, 2000
18) Lee SS, Rudiger T, Odenwald T, Roth S, Starostik P, Muller-Hermelink HK. Angioimmunoblastic T cell lymphoma is derived from mature T-helper cells with varying expression and loss of detectable CD4, Int J Cancer 103:12-20, 2003
19) Zettl A, Lee SS, Rudiger T, Starostik P, Marino M, Kirchner T, Ott M, Muller-Hermelink HK, Ott G. Epstein-Barr virus-associated B-cell lymphoproliferative disorders in angioimmunoblastic T-cell lymphoma and peripheral T-cell lymphoma, unspecified, Am J Clin Pathol 117:369-379, 2002
20) Tan BT, Warnke RA, Arber DA. The frequency of B- and T-cell gene rearrangements and Epstein-Barr virus in T-cell lymphomas: a comparison between angioimmunoblastic T-cell lymphoma and peripheral T-cell lymphoma, unspecified with and without associated B-cell proliferations, J Mol Diagn 8:466-475, 2006
21) Siegert W, Nerl C, Agthe A, Engelhard M, Brittinger G, Tiemann M, Lennert K, Huhn D. Angioimmunoblastic lymphadenopathy (AILD)-type T-cell lymphoma: prognostic impact of clinical observations and laboratory findings at presentation, Ann Oncol 6:859-864, 1995
22) Reiser M, Josting A, Soltani M, Staib P, Salzberger B, Diehl V, Engert A. T-cell non-Hodgkin’s lymphoma in adults: clinicopathological characteristics, response to treatment and prognostic factors, Leuk Lymphoma 43:805-811, 2002
23) Park BB, Ryoo BY, Lee JH, Kwon HC, Yang SH, Kang HJ, Kim HJ, Oh SY, Ko YH, Huh JR, Lee SS, Nam EM, Park KW, Kim JH, Kang JH, Bang SM, Park S, Kim K, Park K, Suh C, Kim WS. Clinical features and treatment outcomes of angioimmunoblastic T-cell lymphoma, Leuk Lymphoma 48:716-722, 2007